What is Xeljanz (UK) used for?
Xeljanz (tofacitinib) is a prescription medicine used to treat certain inflammatory and autoimmune conditions, including some forms of rheumatoid arthritis and other immune-mediated diseases, depending on the exact UK indication and eligibility criteria [1].
What does “Xeljanz UK” usually mean in practice?
People searching “Xeljanz UK” most often want one of these:
- The UK prescribing information (SmPC) and patient-facing guidance.
- NHS/UK availability and how it’s prescribed.
- Dosing for a specific condition.
- Safety warnings and monitoring requirements in the UK.
Those details are set out by the UK regulator through the product’s UK documents (SmPC) [1].
Where can I find the official UK information?
For the most reliable UK-specific details (indications, dose, contraindications, warnings, and monitoring), use the UK product documents for Xeljanz (tofacitinib), typically hosted by the Medicines and Healthcare products Regulatory Agency (MHRA) or related official UK medicine information sources [1].
Safety and monitoring questions UK patients ask
UK prescribing documents for tofacitinib cover risks and the monitoring needed during treatment, such as infection risk and blood test monitoring requirements, along with when treatment should be interrupted or stopped [1].
Is Xeljanz still available in the UK?
Availability can depend on current commissioning, local formularies, and licensing for each indication. The authoritative starting point for what is currently authorised in the UK is the latest UK product information for Xeljanz (tofacitinib) [1].
---
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz